The fund, which has already secured nearly 50% of its target, continues MxEP's strategy of investing in early-stage healthcare companies across diagnostics, therapeutics, medtech, and pharma services. MI2 aims to back around 15 EU-based ventures, targeting scalable platform technologies with proof of concept, scientific strength, and reduced binary risk. Initial investments will typically be around '6m, with follow-ons potentially rising to '15m. 'With our continued Innovation strategy, we will target companies with a proof of concept and potential to scale and create value in the long term,' said Valerie Calenda, managing partner and head of Innovation. MI2's first investment supports deepull's '50m oversubscribed Series C round, co-led by Columbus Venture Partners, Panakes Partners, and Merieux Equity Partners. Other participants included Asabys Partners, Kurma Partners, and additional existing investors. Founded by Jordi Carrera and Rafel Bru'also co-founders of STAT-Dx (acquired...
learn more
